SCHEMBL2170075

SCHEMBL2170075

CC1(C)C(=O)N(C2C3CC4CC(C3)CC2C4)N1C(=O)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.42

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 1/20 0.41
HPGD P15428 1/20 0.40
PKM P14618 1/20 0.38
PGR P06401 2/20 0.36
SCN9A Q15858 3/20 0.36
TSHR P16473 1/20 0.36
KMO O15229 2/20 0.36
KMT2A Q03164 1/20 0.35
HSD11B1 P28845 2/20 0.35
F2 P00734 1/20 0.34
PLAU P00749 1/20 0.34
KLKB1 P03952 1/20 0.34
ELANE P08246 1/20 0.34
ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2169179 0.87 KMT2A (0.39) CHRNA7HPGDKMT2AALDH1A1
SCHEMBL2169563 0.85 P2RX7 (0.40) PKMKMT2AHSD11B1ALDH1A1
SCHEMBL2169689 0.84 P2RX7 (0.35) TSHRHSD11B1
SCHEMBL13368830 0.83 USP2 (0.39) ELANE
SCHEMBL2169195 0.83 PKM (0.40) HPGDPKMKMT2AHSD11B1ALDH1A1
SCHEMBL2171870 0.83 TP53 (0.41) TSHRHSD11B1ALDH1A1
SCHEMBL2170502 0.83 RAB9A (0.43) HPGDTSHRKMT2A
SCHEMBL2170348 0.82 USP2 (0.38) HPGDKMT2AHSD11B1
SCHEMBL2170275 0.82 ALDH1A1 (0.40) KMT2AHSD11B1F2ALDH1A1
SCHEMBL2170194 0.82 USP2 (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8252781-B2 1,2-diazetidin-3-one derivatives and drugs containing same KOWA COMPANY, LTD. (JP) 2012-08-28 US disclosed
US-8252781-B2 1,2-diazetidin-3-one derivatives and drugs containing same KOWA COMPANY, LTD. (JP) 2012-08-28 US disclosed
US-8252781-B2 1,2-diazetidin-3-one derivatives and drugs containing same KOWA COMPANY, LTD. (JP) 2012-08-28 US disclosed
EP-2348019-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVE AND PHARMACEUTICAL AGENT COMPRISING SAME Kowa Company, Ltd. (JP) 2011-07-27 EP disclosed
US-20100144694-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME KOWA COMPANY, LTD. (JP) 2010-06-10 US disclosed
US-20100144694-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME KOWA COMPANY, LTD. (JP) 2010-06-10 US disclosed
US-20100144694-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME KOWA COMPANY, LTD. (JP) 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144694-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME HSD11B1, HSD11B2, HSD3B1 CHRNA7 1777/4885HPGD 101/4885PKM 2561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.